Use of MRP8/14 in clinical practice as a predictor of outcome after methotrexate withdrawal in patients with juvenile idiopathic arthritis
Authors:
- Emma J WelshEWEmma J Welsh
Open Access
- 29 April 2022
- journal article
- research article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 41 (9) , 2825-2830
Abstract
The objective of this study was to determine the effectiveness of MRP8/14 as a predictor of disease flare in patients with juvenile idiopathic arthritis (JIA) following the withdrawal of methotrexate (MTX) in a routine clinical setting. All MRP8/14 tests performed at a single centre in a 27-month period were considered for analysis. Patients were assessed against criteria for inactive disease and subsequent disease flare. Decisions on whether or not to stop treatment were recorded. MRP8/14 results were assessed in conjunction with clinical information. Clinicians were also surveyed to investigate if MRP8/14 influenced their decision to discontinue MTX where this was available at that time point. One hundred four cases met the inclusion criteria during the study period. Although there was no significant difference in flares between patients with an elevated or low MRP8/14 value, in those who stopped MTX ( n = 22), no patients with a low MRP8/14 (≤ 4000 ng/ml) result flared (follow-up time 12 months). Clinicians reported that for patients with clinically inactive disease and an elevated MRP8/14 result (> 4000 ng/ml), none would advise withdrawal of MTX. Low MRP8/14 was interpreted favourably when considering stopping MTX treatment in patients with JIA. Implementation of MRP8/14 testing has changed clinical practice at this centre. However, the observation that some patients in our cohort who had an elevated MRP8/14 value did not flare after stopping MTX for non-disease-related reasons highlights the need for further biomarkers to predict the risk of flare off medication in JIA and aid clinicians in treatment decisions. Key Points • First study of serum MRP8/14 measurement in clinical practice to inform treatment decisions in patients with JIA. • No patients with a low MRP8/14 test result went on to suffer a disease flare in 12 months of follow follow-up. • Further biomarkers are needed to predict the risk of flare off medication in JIA and treatment decisions.Keywords
Funding Information
- UK National Institute for Health Research Biomedical Research Centre
- Sparks (17ICH02)
- UK Research and Innovation Medical Research Council (MR/R013926/1)
- UK Research and Innovation Medical Research Council (MC_UU_00002/4)
- Versus Arthritis (22084)
- Versus Arthritis (21593)
- Great Ormond Street Hospital Charity
- Wellcome (WT107881)
This publication has 11 references indexed in Scilit:
- S100A8/A9: From basic science to clinical applicationPharmacology & Therapeutics, 2016
- Alarmin S100A8/S100A9 as a biomarker for molecular imaging of local inflammatory activityNature Communications, 2014
- A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8/14 proteinRheumatology, 2013
- Juvenile idiopathic arthritisThe Lancet, 2011
- Methotrexate Withdrawal at 6 vs 12 Months in Juvenile Idiopathic Arthritis in RemissionA Randomized Clinical TrialJAMA, 2010
- Patterns of clinical remission in select categories of juvenile idiopathic arthritisArthritis & Rheumatism, 2005
- Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis.2004
- Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammationClinica Chimica Acta, 2004
- International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.2004
- Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop?Annals of the Rheumatic Diseases, 2004